semaglutide oral obesity Gets FDA Approval for CV Event Reduction in High-risk Diabetes Patients Everything You Need To Know

She adds another explanation for why some individuals might seem to observe this association: Weight gain is also linked to the perimenopausal and post-menopausal state, and a GLP-1 is a reasonable treatment for this for those who qualify. What this means is that for some women, the weight loss effects of a GLP-1 and the symptoms of low estrogen may occur at the same time, making it difficult to tell whether the changes are due to the medication, hormonal shifts, or both

Combined with therapies designed to stimulate growth hormone, it could help stimulate repair and vascular support

Food Chem 77:913

Efficacy of pharmacological therapies in patients with IBS with diarrhoea or mixed stool pattern: systematic review and network meta-analysis